Cogent Biosciences, Inc. (COGT)
30.32
-0.06
(-0.20%)
USD |
NASDAQ |
Oct 07, 12:07
Cogent Biosciences Enterprise Value : 4.731B for Oct. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 06, 2026 | 4.731B |
| October 05, 2026 | 4.815B |
| October 02, 2026 | 4.841B |
| October 01, 2026 | 4.939B |
| September 30, 2026 | 5.013B |
| September 29, 2026 | 4.951B |
| September 28, 2026 | 4.985B |
| September 25, 2026 | 5.062B |
| September 24, 2026 | 4.911B |
| September 23, 2026 | 4.908B |
| September 22, 2026 | 5.117B |
| September 21, 2026 | 5.009B |
| September 18, 2026 | 4.923B |
| September 17, 2026 | 5.214B |
| September 16, 2026 | 5.102B |
| September 15, 2026 | 5.136B |
| September 14, 2026 | 5.251B |
| September 11, 2026 | 5.251B |
| September 10, 2026 | 5.366B |
| September 09, 2026 | 5.383B |
| September 08, 2026 | 5.572B |
| September 04, 2026 | 5.483B |
| September 03, 2026 | 5.516B |
| September 02, 2026 | 5.450B |
| September 01, 2026 | 5.469B |
| Date | Value |
|---|---|
| August 31, 2026 | 5.524B |
| August 28, 2026 | 5.468B |
| August 27, 2026 | 5.883B |
| August 26, 2026 | 5.819B |
| August 25, 2026 | 5.833B |
| August 24, 2026 | 5.735B |
| August 21, 2026 | 5.821B |
| August 20, 2026 | 5.577B |
| August 19, 2026 | 5.842B |
| August 18, 2026 | 5.936B |
| August 17, 2026 | 6.017B |
| August 14, 2026 | 6.027B |
| August 13, 2026 | 5.921B |
| August 12, 2026 | 6.207B |
| August 11, 2026 | 6.159B |
| August 10, 2026 | 6.645B |
| August 07, 2026 | 6.793B |
| August 06, 2026 | 6.691B |
| August 05, 2026 | 6.772B |
| August 04, 2026 | 6.870B |
| August 03, 2026 | 6.187B |
| July 31, 2026 | 6.199B |
| July 30, 2026 | 6.616B |
| July 29, 2026 | 6.309B |
| July 28, 2026 | 6.497B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna, Inc. | 70.95B |
| Arrowhead Pharmaceuticals, Inc. | 8.460B |
| Oncolytics Biotech, Inc. | 70.87M |
| Sangamo Therapeutics, Inc. | 49.74M |
| Sarepta Therapeutics, Inc. | 2.086B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -96.40M |
| Total Expenses (Quarterly) | 96.40M |
| EPS Diluted (Quarterly) | -0.5636 |
| Earnings Yield | -8.06% |
| Normalized Earnings Yield | -7.952 |